• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一剂低分子量肝素片段用于血液透析期间的抗凝。

A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.

作者信息

Ljungberg B, Blombäck M, Johnsson H, Lins L E

出版信息

Clin Nephrol. 1987 Jan;27(1):31-5.

PMID:3815906
Abstract

A low molecular heparin fragment (Fragmin, mol. wt. 4-6000 d), given as a single injection (dose 5000 anti-Xa U), was used as an anticoagulant during hemodialysis in 11 patients. In comparison, our routine heparinization procedure was used; conventional heparin was given as a bolus injection at the start and then as continuous infusion during dialysis to prolong the whole blood activated clotting time (WBACT) 125-175%. Fibrin formation, followed by visual inspection and the measuring of fibrinopeptide A and fibrin monomer concentrations were equally suppressed by the two regimens. WBACT was less prolonged with Fragmin. Anti-Xa activity above 0.39 U/ml was maintained throughout the dialyses with Fragmin. In conclusion a single dose of Fragmin gives sufficient anticoagulation for hemodialysis lasting up to 4 hours.

摘要

一种低分子肝素片段(速碧林,分子量4 - 6000道尔顿),单次注射(剂量5000抗Xa单位),用于11例患者血液透析期间的抗凝。作为对照,采用我们的常规肝素化程序;常规肝素在开始时静脉推注,然后在透析期间持续输注,以使全血活化凝血时间(WBACT)延长125% - 175%。两种方案对纤维蛋白形成的抑制效果相当,通过肉眼观察以及测量纤维蛋白肽A和纤维蛋白单体浓度来评估。使用速碧林时WBACT延长较少。在整个使用速碧林的透析过程中,抗Xa活性维持在0.39单位/毫升以上。总之,单剂量的速碧林可为长达4小时的血液透析提供足够的抗凝作用。

相似文献

1
A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.一剂低分子量肝素片段用于血液透析期间的抗凝。
Clin Nephrol. 1987 Jan;27(1):31-5.
2
Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane.低分子量肝素(法安明)在使用高通透性聚砜膜进行血液透析时的有效抗凝作用。
Clin Nephrol. 1992 Aug;38(2):97-100.
3
[Use of fragmin in program hemodialysis of patients with terminal chronic renal failure].[低分子肝素在终末期慢性肾衰竭患者计划性血液透析中的应用]
Klin Med (Mosk). 2005;83(9):45-9.
4
A low molecular heparin fraction as an anticoagulant during hemodialysis.一种低分子肝素片段,用作血液透析期间的抗凝剂。
Clin Nephrol. 1985 Jul;24(1):15-20.
5
Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion.全血活化凝血时间用于评估血液透析期间肝素活性:单剂量给药与输注给药的比较
Clin Nephrol. 1983 Feb;19(2):82-6.
6
Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.低分子量肝素血液透析:消除体外纤维蛋白形成的剂量要求。
Nephrol Dial Transplant. 1986;1(3):179-87.
7
A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
Clin Nephrol. 1989 Dec;32(6):290-6.
8
Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
Clin Nephrol. 1981 May;15(5):252-8.
9
Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan.
Semin Thromb Hemost. 1990 Oct;16 Suppl:46-54.
10
The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.三种不同肝素给药方案对血浆中肝素浓度及透析器中纤维蛋白形成的影响。
Clin Nephrol. 1981 Mar;15(3):135-42.

引用本文的文献

1
Anticoagulation for people receiving long-term haemodialysis.长期血液透析患者的抗凝治疗。
Cochrane Database Syst Rev. 2024 Jan 8;1(1):CD011858. doi: 10.1002/14651858.CD011858.pub2.
2
An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).一种用于预防血液透析体外循环凝血的可调整达肝素钠剂量方案:安全性和有效性的临床试验(鹦鹉研究)
Can J Kidney Health Dis. 2018 Nov 4;5:2054358118809104. doi: 10.1177/2054358118809104. eCollection 2018.
3
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
达肝素:其在预防和治疗血栓栓塞性疾病方面的药理特性及临床疗效的最新进展
Drugs. 2000 Jul;60(1):203-37. doi: 10.2165/00003495-200060010-00010.
4
Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.达肝素钠。其药理学及在预防和治疗血栓栓塞性疾病中的临床应用综述。
Drugs. 1996 Aug;52(2):276-305. doi: 10.2165/00003495-199652020-00011.
5
Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.普通肝素和低分子量肝素的药物治疗学方面
Drugs. 1990 Oct;40(4):498-530. doi: 10.2165/00003495-199040040-00003.
6
Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin).急性透析:中性粒细胞弹性蛋白酶作为使用低分子量肝素(速碧林)控制个体抗凝的新参数。
Intensive Care Med. 1991;17(1):52-6. doi: 10.1007/BF01708410.